Neutre
Pfizer's stock stabilizes at $27.95 after FDA approves new COVID-19 vaccine.
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Pfizer's stock remains steady following the FDA's approval of its updated COVID-19 vaccine for the 2026/27 season. The vaccine is authorized for seniors and high-risk individuals, with shipments to U.S. pharmacies, hospitals, and clinics beginning immediately. However, the FDA has revoked the emergency use authorization for Pfizer's COVID-19 vaccine in children under five years old.
Points clés
- FDA approves Pfizer's updated COVID-19 vaccine for seniors and high-risk individuals.
- FDA revokes emergency use authorization for Pfizer's COVID-19 vaccine in children under five.
- Pfizer's stock price remains near analyst target of $28.28.
Sources
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
